Synthekine STK-012 (Solid Tumors) - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to find out if an experimental drug called STK-012 (the study drug) is a safe and effective treatment for different types of cancer.
Advanced Solid Tumors
¿Quién puede participar en el Estudio?
Adults diagnosed with any of the following cancers that have spread:
- Non-small cell lung cancer (NSCLC)
- Head and neck squamous-cell carcinoma (HNSCC)
- Melanoma
- Renal cell carcinoma (RCC)
- Cáncer cervical
- Urothelial carcinoma
- Cáncer gástrico
- Microsatellite instability-high or mismatch repair deficient cancers (MSI-H/dMMR)
Para obtener más información sobre quién puede participar en este estudio, comuníquese con el equipo del estudio al 919-681-6468.
¿Qué Implica?
If you choose to join this study, the study regimen you receive will depend on what part of the study you join. There are 4 parts to this study:
- In Part A, study participants will get the study drug on its own every week.
- In Part B, study participants will get the study drug on its own every 3 weeks.
- In Part C, study participants will get the study drug every 3 weeks in combination with pembrolizumab.
- In Part D, study participants will be assigned to get the study drug every 3 weeks either on its own or in combination with pembrolizumab.
Before you make a decision, the study doctor will let you know which part of the study is enrolling at the time.
Regardless of which part of the study you join, during this study you will also:
Provide tumor tissue
Have physical exams, blood draws, and give urine samples
Hacerse estudios de imágenes (tomografía computarizada y resonancia magnética)
Have heart tests (ECG)
Detalles del Estudio
